SERUM NEURON-SPECIFIC ENOLASE LEVEL AS A PROGNOSTIC FACTOR IN NONSMALL CELL LUNG-CANCER

被引：16

作者：

ANDOH, M

GEMMA, A

TAKENAKA, K

HISAKATSU, S

YAMADA, K

USUKI, J

HASEGAWA, K

SAKONJI, M

KUDOH, S

TSUBOI, E

NIITANI, H

机构：

[1] Fourth Department of Internal Medicine, Nippon Medical School, Bunkyo-ku, Tokyo, 113

[2] Tsuboi Memorial Hospital, Kouriyamashi

来源：

INTERNAL MEDICINE | 1994年 / 33卷 / 05期

关键词：

TUMOR MARKER; NEUROENDOCRINE PROPERTY; PROGNOSIS;

D O I：

10.2169/internalmedicine.33.271

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In 93 patients with inoperable non-small cell lung carcinoma who underwent chemotherapy including cisplatin, the prognostic value of 9 factors were determined using Cox's proportional hazard model. Univariate analysis revealed that patients with a performance status of grade 2 (p<0.01) or 3 (p<0.05), those with stage IV disease (p<0.05), those with a serum neuron specific enolase (NSE) level >7.0 ng/ml (p<0.001), and those with a low serum albumin level (p<0.05) had a significantly worse prognosis. Multivariate analysis showed that a performance status of 2 or 3 and a high NSE serum level were associated with a significantly worse prognosis. More attention should be paid to the serum NSE level in patients with non-small cell lung carcinoma, because it not only reflects the tumor volume, but is also a prognostic factor which is dependent on individual tumor characteristics.

引用

页码：271 / 276

页数：6

共 25 条

[1]

Linnoila R.I., Mulshine J.L., Steinberg S.M., Et al., Neuroendocrine differentiation in endocrine and non-endocrine lung carcinomas, Am J Clin Pathl, 90, 641, (1988)

[2]

Margolis M.L., Desai B., Gracely E., Et al., Frequency and clinical implications of monoclonal antibody detection of tumor-associated antigens in serum of patients with lung cancer, Am Rev Respir Dis, 142, 1059, (1990)

[3]

Berendson H.H., Leij L., Poppema S., Et al., Clinical characterization of NSCLC tumor showing neuroendocrine differentiation features, J Clin Oncol, 7, 1614, (1989)

[4]

Graziano S.L., Mazid R., Newman N., Et al., The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with NSCLC, J Clin Oncol, 7, 1398, (1989)

[5]

Sundaresan V., Reeve J.G., Steinning S., Et al., Neuroendocrine differentiation and clinical behaviour in NSCLC tumors, Br J Cancer, 64, 333, (1991)

[6]

General rule for clinical and pathological record of lung cancer, (1987)

[7]

Rapp E., Peter J.L., Willan A., Et al., Chemotherapy can prolong survival in patients with advanced NSCLC-Report of a Canadian multicenter randomised trial, J Clin Oncol, 6, 653, (1988)

[8]

Einhorn L.H., Loehrer P.J., Williams S.D., Et al., Random prospective study of vindesine versus vindesine plus high dose cisplatin versus vindesine plus mitomycin C in advanced non-small-cell lung cancer, J Clin Oncol, 4, 1037, (1988)

[9]

Cella D.F., Cherin E.A., Measuring quality of life in patients with cancer. Proceeding of The Fifth National Conference on Human Value and Cancer, Am Cancer Soc, (1987)

[10]

Cox D.R., Regression models and lifetables, J R Stat Soc, 34, 187, (1972)

← 1 2 3 →